BofA upgraded Novavax to Neutral from Underperform with a price target of $12, up from $4.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- NVAX Earnings: Novavax Soars After Stellar Growth in Revenue, Sanofi Deal Boost
- Options Volatility and Implied Earnings Moves Today, May 10, 2024
- Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
- Novavax stockholder Shah Capital issues letter against board re-election
- NVAX Earnings this Week: How Will it Perform?